Impax shares drop as FDA flags new concerns on manufacturing plant
(Reuters) – Impax Laboratories Inc said U. S. health regulators raised fresh concerns related to manufacturing practices at the drugmaker’s Hayward, California facility, sending its shares down more than 20 percent after the bell. The company’s hopes of securing an approval for its Parkinson’s drug Rytari are tied to its ability to resolve issues at the plant, where the drug is partly manufactured. The U. S. . . .
View full post on Health News Headlines – Yahoo! News
Leave a Reply